NEW YORK (GenomeWeb News) — Amaxa said today that it will coordinate an eight-member European alliance to develop devices for ultra-high-throughput transfection of primary cells.
The European Commission awarded the partnership more than €2.75 million ($3.7 million) in funding. The group will use Amaxa’s Nucleofector technology, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.